Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49,625,327
-
Total 13F shares
-
22,652,478
-
Share change
-
-373,355
-
Total reported value
-
$115,539,883
-
Put/Call ratio
-
41%
-
Price per share
-
$5.10
-
Number of holders
-
80
-
Value change
-
-$1,871,335
-
Number of buys
-
40
-
Number of sells
-
36
Institutional Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q3 2025
As of 30 Sep 2025 Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) had 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 22,652,478 shares of stock of the company.
Largest 10 holders included FMR LLC, ACORN CAPITAL ADVISORS, LLC, BlackRock, Inc., VANGUARD GROUP INC, Portolan Capital Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, Halter Ferguson Financial Inc., STATE STREET CORP, Sands Capital Alternatives, LLC, and NORTHERN TRUST CORP.
This table shows 80 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.